Treats acute lymphoblastic leukemia (ALL). ANDA 40054, held by Hikma Pharmaceuticals. Methotrexate Sodium.
As of Nov 21, 2026, ANDA 40054 (Methotrexate Sodium), held by Hikma Pharmaceuticals, was first approved by FDA on Aug 1, 1994, with 9 approved supplements and 0 published complete response letters.
Methotrexate Tablets are a dihydrofolate reductase inhibitor indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 1, 1994 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methotrexate SodiumEQ 2.5MG BASE ยท tablet;oral | Methotrexate Sodium | Rx |
| May 27, 2026 | Supplement 19Labeling ยท Standard review | Approved | None posted |
| Oct 29, 2020 | Supplement 17Labeling ยท Standard review | Approved | |
| Oct 29, 2020 | Supplement 16Labeling ยท Standard review | Approved | |
| Oct 29, 2020 | Supplement 15Labeling ยท Standard review | Approved | |
| Nov 26, 2007 | Supplement 5Labeling | Approved | None posted |
| Sep 13, 2006 | Supplement 4Labeling | Approved | None posted |
| Oct 30, 2001 | Supplement 3Labeling | Approved | None posted |
| May 7, 1998 | Supplement 2Labeling | Approved | None posted |
| Nov 10, 1994 | Supplement 1Labeling | Approved | None posted |
| Aug 1, 1994 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters